Ignite Creation Date:
2024-05-05 @ 4:51 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00320229
Status:
TERMINATED
Last Update Posted:
2006-05-16
First Post:
2006-04-18
Brief Title:
Half-Dose Intracoronary Abciximab Bolus Improves the Mortality Outcome Compared to Standard Intravenous Regimen
Sponsor:
Azienda Sanitaria Ospedaliera
Organization:
Azienda Sanitaria Ospedaliera
Study Overview
Official Title:
None
Status:
TERMINATED
Status Verified Date:
2006-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of our study was to demonstrate that during a percutaneous coronary intervention even smaller amounts of abciximab than standard dose injected locally could achieve a rapid thrombus resolution and clinical improvement without concomitant differences in hemorrhagic complications
Detailed Description:
Patients both with acute myocardial infarction and unstable angina are prone to extensive intracoronary thrombosis leading to acute deterioration during percutaneous coronary intervention or thrombosis of the device despite therapy Intracoronary use of abciximab has reported favourable results We randomly assigned 84 patients to intracoronary half abciximab bolus group A and to standard regimen group B
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None